Cervical cancer
Conditions
Interventions
Trial group:Two spatially segmented brachytherapy + external irradiation at 45 Gy/25 f (PGTVnd dose pushed to 60 Gy) + three-dimensional brachytherapy (7 Gy×4 f or 6 Gy×5 f) + chemotherapy (cisplatin
Sponsors
Linfen Central Hospital
Eligibility
Sex/Gender
Female
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Age between 18 and 75 years; 2. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1; 3. Histologically confirmed cervical cancer (including squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma), FIGO 2018 stage IB3 to IVA; maximum tumor diameter >=6 cm (measured by MRI); 4. No distant metastasis (M0); 5. No prior pelvic radiotherapy or systemic anti-tumor therapy; 6. Able to undergo brachytherapy; 7. Bone marrow and organ function meet treatment requirements (ANC>=1.5*10^9/L, PLT>=100*10^9/L, normal liver and kidney function, normal coagulation function, normal thyroid function).
Exclusion criteria
Exclusion criteria: 1. Combined with other malignant tumors or autoimmune diseases; 2. Active infection, HIV positive or during pregnancy; 3. History of serious adverse reactions related to previous immunotherapy; 4. It is known that the patient has a previous allergy to macromolecular protein preparations; 5. Inability to tolerate concurrent chemoradiotherapy or poor compliance.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Acute Toxicity; | — |
Secondary
| Measure | Time frame |
|---|---|
| Tumor Control Status ;Chronic Toxicity ;Quality of Life ;Tumor markers related to immunotherapy; | — |
Countries
China
Contacts
Public ContactGuan Haichao
Linfen Central Hospital
Outcome results
None listed